Navigation Links
The Canadian Foundation for Global Health Announces a Research and Development Partnership with Medizone International, Inc.
Date:2/18/2009

OTTAWA, Feb. 18 /PRNewswire-FirstCall/ -- It was announced today that Medizone International's (Pink Sheets: MZEI) AsepticSure(TM) hospital sterilization system is being developed under the direction of Dr. Michael E. Shannon of the Canadian Foundation for Global Health. Dr. Shannon was recently appointed President of the Canadian Foundation for Global Health. He also serves as a board member of Medizone International and is the Company's Director of Medical Affairs.

The Medizone AsepticSure(TM) system is described as a portable decontamination and sterilization system for hospitals, government buildings, schools and other functionally critical environments that might currently require, or need to be prepared for, countermeasures capability from contamination by infectious biological agents such as C difficile, E coli, Pseudomonas aeruginous, MRSA and VRE. The AsepticSure(TM) system is designed to sterilize the space and then return it to full service in two hours or less.

Dr. Shannon stated that "this research partnership is the first for the Foundation and he expects that it will establish a model for other projects in the future. Presently, the Foundation is fully occupied in developing this sterilization program. We are currently identifying principal investigators as well as a suitable research institution at which we plan to focus most of our microbiology for this exciting project. Our intention is to begin independent university trials in the spring with the goal of validating the effectiveness of our new system across a broad range of bacterial and viral pathogens. This will be quickly followed by actual hospital beta testing to confirm the practicability of our decontamination protocols. Based upon innovative new engineering approaches, we remain confident that this research will reliably demonstrate 5 log reductions for most, if not all, of these often fatal bacteria. The implications of such work are indeed profound as these pathogens are considered to be the main causative agents of hospital derived infections and collectively account for tens of thousands of lives lost each year in the US alone. So far we have received a high level of interest from hospitals in both the United States and Canada and expect that if the university trials are as successful as we anticipate, it will be a smooth transition to hospital beta testing of the prototype design which is expected to begin during the 3rd quarter of 2009."

The Canadian Foundation for Global Health is a federally chartered not for profit Canadian Corporation. It has been established to assist in the research and development of novel and advanced emerging technologies in the field of science and medicine deemed to be of benefit to humanity.

Medizone International, Inc., is a research and development stage company engaged in the development of patented and unpatented technologies and protocols for O3 based bio-oxidative treatment of diseases caused by lipid enveloped viruses, including Acquired Immune Deficiency Syndrome (AIDS), Hepatitis B & C, and Herpes, the decontamination of blood, blood products and veterinarian serum products, and the treatment of external pathogenic conditions. It is currently developing technology to decontaminate and sterilize hospital surgical suites, emergency rooms and intensive care units.

This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.

Contact for the Canadian Foundation for Global Health 613-231-8555

Investor Relations, Medizone International: 800-953-3350 /

web site: www.medizoneint.com


'/>"/>
SOURCE Medizone International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Medical research community needs to speak louder to prevent another Canadian brain drain
2. Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
3. University of Alberta organic chemist receives top young Canadian scientist prize
4. Posit Science Featured in Canadian Documentary on the Brain
5. New Study by BioTrends Highlights Practice Management Shifts Among Canadian Nephrologists
6. Canadian cold/flu breakthrough remedy undergoes NCI-sponsored trial in leukemia patients
7. Natural Nutrition Canadian Subsidiary Signs $50.5 Million (CDN) Five Year European Distribution Contract
8. U of T professor first Canadian woman to win prestigious international science prize
9. Superbugs on the rise in Canadian hospitals, new Queens study shows
10. Leading Insurer Offers Education on How Supplemental Insurance Can Help Offset Challenging Economic Trends in Canadian Market
11. DIA 6th Canadian Annual Meeting Benefit and Risk Management: An Evolution in Progress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Finally, a bruise cream that really works. Originally designed ... into the post-surgical treatment plans of a variety of other procedures including, but not ... effective for bruising and causes a rapid resolution of bruising and inflammatory changes compared ...
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially ... their medication by matching users with high quality water pipes within an ideal price ... commitment. , Inhale was founded by two brothers, Nick and Mike Hunter, who use ...
(Date:6/23/2016)... ... June 23, 2016 , ... Terumo BCT, ... organization responsible for clinical transfusion research programs and for the blood supply in ... Evaluation and Predictive Analytical Rating Score (PREPAReS) study. , Currently in its ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, ... throughout Jasper County and the surrounding region, is initiating a charity drive to assist ... raise funds earmarked for a scholarship fund that will be presented to the chosen ...
(Date:6/23/2016)... , ... June 23, 2016 , ... Representatives of CHA ... the newest member of their staff, Dr. Joshua J. Berger. As of May ... of the world-renowned facility. , Dr. Berger has received recognition for his research, his ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Global Blood Therapeutics, Inc. (GBT) (NASDAQ: ... novel therapeutics for the treatment of grievous blood-based ... closing of its previously announced underwritten public offering ... public offering price of $18.75 per share. All ... by GBT. GBT estimates net proceeds from the ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
Breaking Medicine Technology: